tag:blogger.com,1999:blog-2741672436160438708.post8966278637766740520..comments2024-03-26T12:50:32.070-07:00Comments on Learning from and about cancer (chronic lymphocytic leukemia or CLL) by Dr. Brian Koffman: ASCO 2014: Dr. Kipps Discusses ROR1 and Information about a New ROR1 Monoclonal Antibody (cirmtuzumab) Trial in Relapsed and Refractory CLL (chronic lymphocytic leukemia)Brian Koffmanhttp://www.blogger.com/profile/13250684684103918493noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-2741672436160438708.post-16389617153371670692014-09-24T15:45:34.809-07:002014-09-24T15:45:34.809-07:00In talking to the ROR1 Trial Coordinator yesterday...In talking to the ROR1 Trial Coordinator yesterday at UCSD he said they have one patient who has started the therapy.Terry Evansnoreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-4743145850152656682014-09-24T08:34:50.856-07:002014-09-24T08:34:50.856-07:00Probably wishful thinking that any initial finding...Probably wishful thinking that any initial findings on cirmtuzumab will be presented @ ASH? I am wondering if Dr. Kipps expects cirmtuzumab to be more active than CD20 mAbs at clearing CLL from marrow and nodes. Seems as if mAbs are effective at clearing peripheral blood, Ibrutinib at nodes, and ABT-199 in marrow. <br /><br />It probably takes more time to begin actual treatment under the ROR1 CAR trial. I believe Dr Wierdas trial opened this summer also, so maybe the first patients have begun treatment?!<br /><br />This is my Super Bowl... Can wait for the next play.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-86776468162505981542014-09-24T06:44:15.283-07:002014-09-24T06:44:15.283-07:00Great news Brian. Thanks for getting this informa...Great news Brian. Thanks for getting this information to us.Anonymousnoreply@blogger.com